Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Blood Cells, Molecules & Diseases

• Publication date

  2015-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bcmd.2014.11.017PMID 25486927
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

  2014cited by this paper
• Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis

  2014cited by this paper
• IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution

  2014cited by this paper
• Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations

  2014cited by this paper
• Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients

  2012cited by this paper
• IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB‐M2 subtype

  2012cited by this paper
• IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome

  2012cited by this paper
• Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

  2012cited by this paper
• IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

  2011cited by this paper
• Clinical effect of point mutations in myelodysplastic syndromes.

  2011cited by this paper
• Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients

  2011cited by this paper
• Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

  2011cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.

  2010cited by this paper
• IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

  2010cited by this paper
• Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

  2010cited by this paper
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

  2010cited by this paper
• Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

  2010cited by this paper
• WHO-defined ‘myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations

  2010cited by this paper
• IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

  2010cited by this paper
• Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

  2010cited by this paper
• Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

  2010cited by this paper
• Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

  2010cited by this paper
• IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

  2010cited by this paper
• IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms

  2010cited by this paper
• IDH mutation analysis is not suitable for the routine molecular diagnostic algorithm in myeloproliferative and myelodysplastic neoplasms.

  2010cited by this paper
• IDH mutations in glioma and acute myeloid leukemia.

  2010cited by this paper
• Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q)

  2010cited by this paper
• Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms.

  2010cited by this paper
• IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

  2010cited by this paper
• IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors

  2009cited by this paper
• Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• The impact of JAK2 non‐receptor tyrosine kinase mutation on the mobilization of hematopoietic stem cells into peripheral blood of patients with Philadelphia chromosome‐negative myeloproliferative disorders

  2009cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Acute myeloid leukaemia.

  2006cited by this paper
• Acute myeloid leukemia.

  1999cited by this paper
• Peroxisomal NADP-Dependent Isocitrate Dehydrogenase. Characterization and Activity Regulation during Natural Senescence.

  1999cited by this paper
• Leukemia arising out of paroxysmal nocturnal hemoglobinuria.

  1999cited by this paper
• Preleukemia: Cytogenetic Clues in Some Confusing Disorders

  1977cited by this paper

• PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study

  2025cites this paper
• Molecular Analysis of Genes CEBPA, NPM1, IDH1, and RUNX1 Polymorphisms as Biomarker Potential in Leukemia Patients

  2024cites this paper
• IDH2: A novel biomarker for environmental exposure in blood circulatory system disorders

  2022cites this paper
• Unconventional Diagnosis Based on Somatic Findings through Germ Line Whole-Exome Sequencing.

  2020cites this paper
• Analysis 0f TET-2, ASXL1, IDH1, IDH2 Gene Polymorphisms and The Correlation with Clinical Parameters in Patients With Myelodysplastic Syndrome

  2020cites this paper
• PROGNOSTIC IMPACT OF ISOCITRATE DEHYDROGENASE ENZYME ISOFORMS IDH1 & IDH2 MUTATIONS IN ACUTE MYELOID LEUKEMIA

  2019cites this paper
• The Road to Pathogenesis: Charting the Development of LSCs and Pre-LSCs

  2019cites this paper
• Mutational Profiling of Pediatric Myeloid Leukemia Subtypes without Clinically Significant Chromosomal Aberrations

  2019cites this paper
• Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML

  2019cites this paper
• A particular case of AML patient with the polymorphism G105G (rs11554137) and the missense mutation R132C in IDH1 gene

  2018cites this paper
• TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms

  2017cites this paper
• IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes

  2017cites this paper
• Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia

  2017cites this paper
• Pathogenesis of Clonal Dominance in PNH: Growth Advantage in PNH

  2017cites this paper
• Myeloproliferative neoplasms: Current molecular biology and genetics.

  2016cites this paper
• Physiological and pathological implications of 5-hydroxymethylcytosine in diseases

  2016cites this paper
• Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype

  2016cites this paper
• Isocitrate dehydrogenase mutations in myeloid malignancies

  2016cites this paper
• Genetic Mutations in Acute Myeloid Leukemia

  2016cites this paper
• Białka TET a modyfikacje epigenetyczne w nowotworach TET proteins and epigenetic modifications in cancers

  2015cites this paper
• The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis

  2015cites this paper
• Gene Mutations in Acute Myeloid Leukemia — Incidence, Prognostic Influence, and Association with Other Molecular Markers

  2015cites this paper
• [TET proteins and epigenetic modifications in cancers].

  2015cites this paper
• Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

  2015cites this paper
• Detection of Dual IDH 1 and IDH 2 Mutations by Targeted Next-Generation Sequencing in Acute

  2015cites this paper